NWF Advisory Services Inc. Has $2.09 Million Holdings in Amgen Inc. $AMGN

NWF Advisory Services Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 41.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,766 shares of the medical research company’s stock after selling 4,116 shares during the quarter. NWF Advisory Services Inc.’s holdings in Amgen were worth $2,088,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of AMGN. Adell Harriman & Carpenter Inc. raised its stake in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Amgen during the fourth quarter valued at approximately $22,441,000. National Pension Service increased its holdings in shares of Amgen by 4.7% in the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock valued at $405,717,000 after purchasing an additional 55,489 shares in the last quarter. Integrated Advisors Network LLC increased its holdings in shares of Amgen by 50.5% in the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Amgen by 2.5% in the 4th quarter. Legal & General Group Plc now owns 3,811,451 shares of the medical research company’s stock worth $1,247,526,000 after purchasing an additional 94,494 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $362.00 price objective on shares of Amgen in a report on Wednesday, August 19th. Wells Fargo & Company boosted their target price on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein upped their price target on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Bank of America raised their price target on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $380.43.

Amgen Price Performance

Shares of AMGN stock opened at $444.12 on Friday. The firm’s 50 day moving average price is $395.82 and its two-hundred day moving average price is $366.66. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $447.03. The stock has a market cap of $240.11 billion, a PE ratio of 27.60, a PEG ratio of 3.19 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s payout ratio is 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last quarter. 0.85% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.